Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries.
Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
The story of Novo Nordisk goes back more than 80 years. It began when August Krogh, a Nobel Prize-winning professor at the University of Copenhagen, decided he wanted to start producing a revolutionary new medical preparation called insulin.
The Triple Bottom Line -
our way of doing business
We believe that a healthy economy, environment and society are fundamental to long-term business success. This is why we manage our business in accordance with the Triple Bottom Line business principle and pursue business solutions that maximise value to our stakeholders as well as our shareholders.
In practice, this means that any decision should always seek to combine three considerations: is it financially, socially and environmentally responsible? This way, we continuously optimise our business performance and enhance our contribution to the societies we operate in.
Affiliates or offices in 75 countries
Approximately 41,500 employees (December 2014)
More facts and figures here
Novo Nordisk A/S
Novo Allé, 2880 Bagsvaerd